Defymed MailPan (pre-vascularized refillable macroencapsulation pouch) & ExOlin

Overview

Defymed (spun out of the Centre Européen d'Etude du Diabète [CEED] in Strasbourg, France, led by Dr. Séverine Sigrist) is developing two closely related implantable extraperitoneal medical devices built around a planar, semi-permeable polymer membrane pouch:

1. MailPan® (MAcroencapsulation of PANcreatic Islets): A refillable bioartificial pancreas designed to house insulin-producing cells (deceased-donor islets, stem-cell-derived islets, or porcine islets) behind an immune-isolating membrane without systemic immunosuppression (PMID: 32523669, PMID: 39950714).
2. ExOlin® (EXtraperitoneal Physiological INSulin Delivery): An acellular physiological insulin-delivery pouch that uses the same extraperitoneal membrane architecture connected to an external insulin pump catheter to diffuse liquid insulin across a broad vascularized surface toward the portal vein (PMID: 32014565, NCT05221359).

How MailPan & ExOlin Work

1. MailPan: Pre-Vascularization + Subcutaneous Refill Ports

Traditional sealed macroencapsulation devices fail in part because freshly transplanted islets are placed into an avascular surgical pocket where hypoxia kills the core of the graft within days, and once cells die the entire device must be surgically excised. MailPan addresses this with a two-step protocol (PMID: 32523669):

• Step 1 — Empty Implantation & Pre-Vascularization: The flat circular membrane pouch is implanted empty into the extraperitoneal space (just outside the peritoneal cavity, avoiding intraperitoneal bowel adhesions) along with two connected subcutaneous access ports. Over several weeks, a dense host capillary network forms around the outer polyester/polyurethane membrane without fibrotic foreign-body closure.
• Step 2 — Percutaneous Cell Loading & Refilling: Once the tissue bed is vascularized, insulin-producing cells (often supplemented in preclinical work with marine hemoglobin oxygen carriers M101/M201 to buffer early hypoxia, PMID: 37318185) are injected percutaneously through the subcutaneous filling port into the flat chamber. If graft function declines months or years later, the chamber can be flushed and reloaded with fresh cells through the ports without repeat surgery.

2. ExOlin: First-in-Human Extraperitoneal Insulin Pilot (Pilot'Ex, NCT05221359)

To validate the surgical implantation, extraperitoneal tissue tolerance, and trans-membrane diffusion kinetics in humans prior to cell-loaded trials, Defymed launched the Pilot'Ex study (NCT05221359) at University Hospital Strasbourg (n = 8 estimated adults with poorly controlled T1D failing subcutaneous pump therapy and struggling to stay within 70–180 mg/dL [3.9–10.0 mmol/L]). In ExOlin, liquid rapid-acting insulin infused into the pouch diffuses across the vascularized extraperitoneal membrane and is absorbed directly into the portal venous circulation — aiming to replicate the rapid pharmacokinetics of implantable intraperitoneal pumps (such as DiaPort or Medtronic MIP) while preventing peritoneal catheter tip encapsulation and blockages (PMID: 32014565).

Limitations & Watch Items

1. Zero Human Clinical Data for Cell-Loaded MailPan: It is essential not to confuse NCT05221359 (ExOlin, which infuses pharmaceutical liquid insulin with no living cells) with a clinical trial of MailPan. As of October 2026, cell-loaded MailPan remains preclinical.
2. The Closed-Membrane Oxygen Bottleneck: Every closed diffusion macroencapsulation device tested in humans to date (Beta-O2 βAir, ViaCyte PEC-Encap / VC-01, and Vertex VX-264, discontinued in March 2025) has struggled to sustain therapeutic human C-peptide levels without direct intra-islet capillary ingrowth (sernova-bio-hybrid-organ) or ultra-thin conformal membranes (encellin-encapsulation). Whether MailPan's pre-vascularization, flexible mesoporous polyurethane membranes (PMID: 39950714), and oxygen carriers (PMID: 37318185) can overcome that diffusion limit at a full human replacement dose remains unproven in people.

Summary of Strengths & Limitations

Strengths

• Two-step pre-vascularized implantation plus subcutaneous filling and emptying ports allow insulin-producing cells to be injected — and non-surgically flushed out and replaced when grafts fatigue — after host capillaries have already formed around the membrane
• Peer-reviewed allogeneic diabetic rat studies (Magisson et al., Journal of Tissue Engineering 2020) and recent mesoporous polyurethane membrane upgrades (Gross et al., 2025) demonstrated biocompatibility, vascularization, and immune isolation without systemic immunosuppression
• The underlying extraperitoneal membrane hardware is being tested in humans via Defymed's companion ExOlin physiological liquid-insulin delivery device at University Hospital Strasbourg (Pilot'Ex, NCT05221359)

Limitations

• Zero human clinical trials or human C-peptide data exist for cell-loaded MailPan as of October 2026; NCT05221359 tests only acellular ExOlin delivering exogenous pump insulin
• Planar diffusion macroencapsulation pouches without direct intra-graft capillary ingrowth face severe oxygen and nutrient diffusion bottlenecks when scaled to a full human therapeutic islet dose (~300,000–500,000 IEQ), the same physics that caused Beta-O2 BAir and Vertex VX-264 to fail in human trials
• Requires surgical implantation of the extraperitoneal pouch and subcutaneous access ports